CONTACT
Group Companies
Company Statements
Biocon Biologics Statement on the Status of Bevacizumab FDA Action Date in Dec 2020
-
Fri, 25-Dec-2020
- Posted by: BIOCON
No Comments
Biocon Biologics and Mylan Receive CHMP Recommendation for Approval of Biosimilar Insulin Aspart
-
Mon, 14-Dec-2020
- Posted by: BIOCON
Biocon Biologics Drug Substance Facilities in Bengaluru Receive EU GMP Certification
-
Tue, 12-May-2020
- Posted by: BIOCON
Biocon Receives EIR for Small Molecules API Manufacturing Facility for Pre -Approval and GMP U.S. FDA Inspection
-
Fri, 08-May-2020
- Posted by: BIOCON
Biocon Biologics Receives EIR from U.S. FDA for Two Manufacturing Facilities, Inspection Stands Closed
-
Thu, 16-Apr-2020
- Posted by: BIOCON
Biocon’s Insulin Manufacturing Facility in Malaysia Receives EIR from U.S. FDA with Voluntary Action Indicated (VAI) Classification, Inspection Stands Closed
-
Wed, 01-Apr-2020
- Posted by: BIOCON
Biocon Receives EIR for Small Molecules API Manufacturing Facility for Post – Approval and GMP U.S. FDA Inspection
-
Fri, 20-Mar-2020
- Posted by: BIOCON
Biocon’s Small Molecules API Manufacturing Facility Completes Post-Approval and GMP U.S. FDA Inspection
-
Thu, 27-Feb-2020
- Posted by: BIOCON
Biocon’s Insulin Manufacturing Facility in Malaysia Completes U.S. FDA (PAI) Inspection
-
Sat, 22-Feb-2020
- Posted by: BIOCON
Biocon’s Small Molecules API Manufacturing Facility Completes Pre-Approval and GMP U.S. FDA inspection
-
Mon, 27-Jan-2020
- Posted by: BIOCON
